Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months

Adagio Therapeutics Inc ADGI has announced new data from its COVID-19 antibody program.
Related Link: Adagio Therapeutics To Expand Late-Stage COVID-19 Antibody Trial.
The Company is evaluating ADG20 in Phase 1 single ascending dose study of ADG20 ex vivo against SARS-CoV-2.
Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg intramuscular (IM) dose that was given as a single injection.
In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the Moderna Inc's MRNA mRNA-1273 vaccine and exceeded those achieved with the AstraZeneca Plc's AZN AZD1222 vaccine series, the Company reported.
ADG20 was well-tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions.
Participants will continue to be followed through for 12 months.
Adagio anticipates that the data will support an Emergency Use Authorization application in Q1 of 2022.
Data from quantitative systems pharmacology/whole-body physiologically based modeling support evaluation of 300 mg intramuscular dose of ADG20 as a single injection in Phase 2/3 studies
Price Action: ADGI stock is up 1.19% at $40 during the market session on the last check Wednesday.